Navigation Links
New sensors developed to predict effectiveness of radiotherapy treatment

The human population is exposed to both natural and artificial sources of radiation, which can cause cancer and other defects. Strangely, the same radiation that causes such effects is used for the treatment of cancer, //referred to as radiotherapy. It is however very difficult to assess if the precise dose of radiation is being delivered.

New sensor systems have now been developed that can assess the effectives of the radiation treatment to improve the accuracy and reliability. The system called as Intensity Modulated Radiotherapy (IMRT) has been developed for real-time radiation monitoring.

The setup sends the external beam radiation from different angles to different regions of the tumor. A collimator modulates and shapes the beams so that the tumour receives a uniform dose. It improves clinical outcomes by more accurately targeting tumors and minimizing the amount of radiation absorbed by healthy tissue.

INVORAD developed two sensors that can perform the task in a simple way. The small size of the sensor, the response to different forms of radiation used in radiotherapy and compatibility of the device with microprocessors offer a superior advantage. The device is based on the working principle of semiconductor material that senses the incoming radiation and transmits it to a display unit.

INVORAD also developed a cylindrical 'body phantom'. The 'phantom' is given the prescribed dose and the sensors pick up the dose actually delivered. If the 'phantom' treatment matches the prescription of the simulator, the patient is given treatment. If not, the treatment plan needs to be corrected.

The two devices are being tested in patients undergoing radiotherapy treatment. If successful, there would soon be commercialization of the sensor system. This is hoped to reduce the side effects patients associated with radiotherapy by improving accuracy of dose delivery, which has a significant impact in cancer tr
'"/>




Page: 1 2

Related medicine news :

1. New ways developed to understand dyslexia
2. Researchers developed world’s smallest toothbrus
3. Blood test developed for malignant hyperthermia
4. New ultralight hand with better functionality and flexibility developed
5. Novel antibiotic dressing developed for improved wound healing
6. New spinal surgery technique developed by UCSF Surgeon
7. Child specific HIV drugs and laboratory tests should be developed
8. Vaccines developed, to treat melanoma in dogs
9. Bionic muscles developed by scientists powered by alcohol and hydrogen
10. Vaccine for ear and sinus infections to be developed…
11. Canadians wait an eternity - Issues of a developed healthcare system.
Post Your Comments:
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begin...l/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ...ced today that its subsidiary has commenced commer...psules USP product in the 40mg,strength from its D...on,with the launch, Watson has 180 days of marketi...
(Date:7/25/2008)...AUMBURG, Ill., July 25 /PRNewswire/ -- Sagent Phar...maceutical company, today announced that it,has la...antiarrhythmic,indicated for the treatment and pro...llation and hemodynamically unstable ventricular,t...ular heart beat.,Sagent,s amiodarone HCl injection...
(Date:7/25/2008)...LSBAD, Calif., July 25 /PRNewswire/ -- AutoGenomic...ration statement on Form S-1 with the,Securities a...itial public,offering of shares of its common stoc...red, all of which are expected to be offered by,Au...ring, have not yet been,determined., J.P. Morgan ...
(Date:7/25/2008)... New program delivers immediate ... [24-hour telephone access to language interprete...ing multilingual solutions. , ... LLE® http://www.lle-inc.com/index.html [(L...ovider of interpretation, translation, and languag...
Breaking Medicine News(10 mins):Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3
...ide a bridge to a transplant.Heart failure is char...le to pump blood around the body. Till now, it has...sible - with the only real cure being a transplant...e (LVAD) is a mechanical pump which is used to sup...
...lly to the heart.Improvements in heart disease ris...smoking. It's known that smoking increases the ris...oxide in cigarette smoke,// which raises cholester...ther heart disease risk factors. Each 1% increase ...
...e more likely to have a specific variant of a bloo... tests on 500 men who had died suddenly, many of w... men younger than 55, a gene variant known as HPA-... common than in the general population.// The gen...
...skin could be better than white at fending off fun... James Mackintosh says it could explain why dark s...al environments. A popular theory on why darker sk... skin in others, is that// the extra melanin in da...
Other Medicine News:
(Date:7/23/2008)...TTLE, July 23 /- Sound Pharmaceutical...ication with the FDA for the clinical,testing of a...tion of,chemotherapy induced hearing loss or ototo...005, will be tested in advanced stage lung cancer,...um based chemotherapy.,This marks the second devel...
(Date:7/23/2008)...TTLE, July 23 /- Dendreon C...t expects the Independent Data,Monitoring Committe...lysis,of overall survival relating to the Company,...Carcinoma Treatment, also known as D9902B) clinica... the Company,s investigational,active cellular imm...
(Date:7/22/2008)...est awards under Therapeutics Development Initiati...ions to 23; next deadline January 20,2009, NEW Y... its mission to,speed delivery of transformative t...Michael J. Fox Foundation for Parkinson,s Research...industry research teams. The awards,were granted u...
(Date:7/22/2008)...Geoffrey Allan Will Stress the Importance to Patie...ics Approval Pathway, RICHMOND, Va., July 22 /PRN...) a developer of follow-on biologics and biopharma....D., CEO of Insmed, will present at a,Congressiona...he,significant need for establishing an approval p...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD 385 1Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD 385 2Adult offspring of parents with PTSD have lower cortisol levels 381 1Adult offspring of parents with PTSD have lower cortisol levels 381 24 Star Gen Barry McCaffrey Former U S Drug Czar to Address National Drug Crisis Keynote Grand Opening of New Allenwood PA National Model Detox C 377 14 Star Gen Barry McCaffrey Former U S Drug Czar to Address National Drug Crisis Keynote Grand Opening of New Allenwood PA National Model Detox C 377 2American Chemical Societys Weekly Presspac Aug 29 2007 218 1American Chemical Societys Weekly Presspac Aug 29 2007 218 2American Chemical Societys Weekly Presspac Aug 29 2007 218 3American Chemical Societys Weekly Presspac Aug 29 2007 218 4American Chemical Societys Weekly Presspac Aug 29 2007 218 5American Chemical Societys Weekly Presspac Aug 29 2007 218 6American Chemical Societys Weekly Presspac Aug 29 2007 218 7American Chemical Societys Weekly Presspac Aug 29 2007 218 8
...NA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - Caland...mpany and a,majority-owned subsidiary of Arrowhead... publication in the Proceedings of the,National Ac...f the,NAS, of the first non-human primate study to... siRNA therapeutic candidate that is a,nanoparticl...
...FIELD, N.J., March 20, 2007 /PRNewswire-FirstCall/...as shown potential to,act as a potent payload in a...o the latest edition of the Handbook of Therapeuti...ews immunotoxins, Susanna,Rybak, Ph.D. summarizes ...ty and potency of ONCONASE improves in a number of...
Other Medicine Technology:Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 2Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 3Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 4Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 5Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4
The NOW® Malaria Test is a field or laboratory test for the differential diagnosis of a Malaria infection. It is intended for the detection of circulating Plasmodium falciparum (P.f.) antigen
Ultraview 1700 Central Monitor
...tient Care Monitor (PCM) and Central Station provi...PCM extends the cardiac cath or electrophysiology ...ath and/or EP procedures, providing both physiomon...device either standalone or on its own network. W...
...nitoring via the Acuity central station and Welch ...nvert non-monitored beds into centrally monitored ...t both wireless and hardwired monitors and clinica...ities from a community hospital to a teaching inst...
Medicine Products: